Introduction
Prekallikrein (PK), the precursor for plasma kallikrein (KK), circulates in complex with plasma high-molecular-weight kininogen (HK) 1 . PK is converted to KK by activated factor XII (αXIIa) on biologic or artificial surfaces by the process of contact activation, in plasma or solution by soluble Hageman factor fragment (βXIIa), or by the endothelial cell-bound serine protease prolylcarboxypeptidase (PRCP) [2] [3] [4] . In the contact activation system (CAS), formed KK, a serine protease, activates zymogen factor XII (XII) to αXIIa in a reciprocal manner, amplifying XII autoactivation to initiate the intrinsic pathway of coagulation leading to thrombin generation and fibrin formation 5 . KK also promotes inflammation through the kallikrein/kinin system (KKS) by cleaving HK in solution and bound to endothelium to liberate the vasoactive peptide bradykinin (BK) 6, 7 . BK binds to constitutively expressed bradykinin B2 receptor (B2R) regulating kininogen binding sites, inducing vasodilation and vascular permeability, and reducing thrombus formation [8] [9] [10] [11] [12] . Intravascular PK activation and BK release are both physiological and pathophysiologic processes, since BK formation regulates vascular tone and the deficiency of the major KK and αXIIa inhibitor, C1 inhibitor, causes constitutive BKmediated angioedema 13 . PK deficiency in humans (Fletcher trait) has a prolonged activated partial thromboplastin time (aPTT) that corrects on longer incubation of plasma in glass tubes 14 . Although PK activation promotes blood coagulation through the CAS, PK deficient patients have no hemostatic defect 14 . Selective reduction of murine PK by antisense oligonucleotides yields reduced thrombus size without bleeding 15 . PK For personal use only. on . by guest www.bloodjournal.org These combined studies indicate that PK deficiency reduces thrombosis without change in hemostasis.
The precise mechanism(s) leading to delayed thrombosis in PK deficient mice is not known. Recent investigations indicate that Bdkrb2 -/-mice, B2R deficient animals, have delayed thrombosis by a novel mechanism whereby two receptors from the reninangiotensin system (RAS), the angiotensin receptor 2 (AT2R) and Mas, become overexpressed to bind angiotensin II (AngII) and angiotensin-(1-7) [Ang-(1-7)], respectively, to increase NO and prostacyclin (PGI 2 ) 17, 18 . We asked if the thrombosis delay in PK deficient mice is due to reduced contact activation, less BK delivery to tissues, or both.
This investigation presents a novel mechanism for thrombosis reduction in Klkb1 -/-mice.
Klkb1
-/-mice have reduced thrombosis risk by a mechanism related to the Bdkrb2 -/-mice whereby over-expression of the Mas receptor is associated with elevated plasma PGI 2.
The enhanced Mas-prostacyclin axis produces increased aortic mRNA and protein of the vasculoprotective transcription factors sirtuin-1 (Sirt1) and Kruppel-like factor 4 (KLF4) with decreased vascular tissue factor (TF). This pathway for thrombosis reduction highlights the interaction between the KKS and RAS independent of the CAS and the importance of the Mas-prostacyclin axis in the modulation of arterial thrombosis risk in vivo.
For personal use only. on All other assays and methods are described in the Supplemental Methods. μM purified human PK such that their aPTTs were corrected to normal (Supplemental Figure 1) , the time [57±7 min (n=5)] to arterial occlusion did not correct ( Figure 1D ).
Results

Characterization of
These data suggested that the mechanism(s) for delayed thrombosis in Klkb1 -/-mice was not entirely due to PK deficiency. Using 4% ferric chloride, we also observed thrombosis delay in Klkb1 -/-mice. All WT animals had complete occlusion in carotid artery within 10 min (5.0±1.2 min, n=5), while Klkb1 -/-mice occluded at 54±6.4 min (n=11) (p<0.001) ( Figure 1E ). These combined data showed that PK deficiency likewise was associated with reduced thrombosis in our models.
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Klkb1
-/-mice have reduced contact activation. KK participates in contact activation by cleaving XII into αXIIa leading to thrombin generation through XI activation of the intrinsic pathway. We determined the plasma thrombin generation times (TGT) in
-/-mice. Consistent with the prolonged aPTT, Klkb1 -/-plasma had defective contact activation-induced TGT ( Figure 1F ). When the Klkb1 -/-plasma was reconstituted with purified human PK to make it 450 nM, the contact activation TGT corrected to normal ( Figure 1F ). There was no contact activation on the TGT with F12 -/-plasma ( Figure 1F ).
The mean peak height of TGT in Klkb1 -/-plasma was 37±7% (n=4) compared to WT plasma (n=8) (p<0.001) (Supplemental Figure 2) . Upon prolonged incubation of Klkb1 -/-plasma for 3 h at room temperature in a glass cuvette, the TGT and mean peak height partially corrected (73±5% compared to WT, n=4), but was still significantly lower than WT plasma (n=8) ( Figure 1G and Supplemental Figure 2 ) (p<0.001). Similarly, the mean total area under the curve (AUC) for contact activation-induced TGT in Klkb1 -/-plasma was 46±8% (n=4) compared to WT plasma (n=8) (p<0.001), which upon 3 h incubation partially corrected to 76±4% (n=4) ( Figure 1H ) (p<0.001). F12 -/-plasma had no AUC ( Figure 1H ). These combined data indicated that Klkb1 -/-plasma had defective contact activation.
We next asked if defective contact activation contributed to the reduced thrombosis risk as observed in F12 -/-mice [20] [21] [22] . Klkb1 -/-mice were examined on both the collagen/epinephrine (Col/Epi) and bacterial long chain polyphosphate (LC polyP) models of lethal pulmonary embolism 21, 22 . In order to confirm that the occluded vessels observed on H&E staining in the previous figure were due to fibrin deposition, additional investigations were performed. Several large vessels in the Col/Epi model had an intraluminal rim of murine fibrin as detected by monoclonal antibody 59D8 ( Figure 3A ) 21 . Additionally, in the lumen of these vessels, platelet thrombi as detected by anti-CD42c were observed also with a fibrin rim ( Figure   3A ). When the microvasculature was examined, Klkb1 +/+ and Klkb1 -/-mice had an equal number of fibrin-occluded vessels matching what was observed on H&E ( Figure 3B ).
Additionally, these microvessels had an equal amount of platelet material within the occluded vessels and the platelet material co-localized with fibrin ( Figure 3C ). This assessment was based upon the confluence of the green (fibrin) and red (platelet) staining to give yellow vessel occlusions ( Figure 3C ). Thus, both the Klkb1 -/-and Klkb1 +/+ mice had similar degrees of fibrin and platelet material in their vessels, the hallmark of lung injury 23 . However, even though there were similar degrees of thrombosis, the degree of lung edema-leakiness was distinctly different. Using Evans blue, Klkb1 -/-mice have significantly reduced vascular permeability when compared to suggesting that the reduced arterial thrombosis observed in these animals may not be just defective contact activation. We sought additional mechanism(s) for the thrombosis delay in Klkb1 -/-mice. . In Bdkrb2 -/-mice the elevated AngII and Ang-
Role of Mas receptor in thrombosis protection in
(1-7) interact with their additionally over-expressed receptors, AT2R and Mas, respectively, to elevate plasma NO and PGI 2 leading thrombosis delay 17, 18 . The proteins and peptides of the KKS and RAS interact at multiple sites to influence thrombosis risk 20, 25 . Since KK cleaves HK to liberate BK, we determined plasma BK levels in PK deficient mice 19, 20 . Klkb1 -/-mice had plasma BK (0.07±0.008 ng/ml, n=6) levels 29-fold less than WT (2±0.8 ng/ml, n=6) (p<0.0001) ( Figure 4B ).
Further, Klkb1 -/-mice have an 80% reduction in renal B2R mRNA ( Figure 4C ).
Additional investigations revealed that renal mRNA for ACE and AT2R was reduced in
Klkb1
-/-mice, but mRNAs for the bradykinin B1 receptor (B1R) and AT1R were normal (Supplemental Figure 3 ). Figure 4G ). Additional studies also showed that renal mRNA for the Ang-(1-7) generating enzymes ACE2 and PRCP were not significantly different between WT and Klkb1 -/-mice (Supplemental Figure 3) .
Further, investigations showed that Klkb1 -/-mice had equal Ang-(1-7) generating activities from ACE2 and PRCP as WT mice (Supplemental Figure 4) . Figure 4H ). Additionally, when WT mice were treated with AVE0991, a Mas agonist, their Mas mRNA increased 6.2-fold (Supplemental Figure 5) and their time to vessel occlusion prolonged to 51±2 min (n=7) ( Figure 4H ). antibody. Likewise, ADP-induced (0.1 to 3 µM) fibrinogen binding was similar between the two genotypes (Supplemental Figure 8) . Additionally, phalloidin staining showed that
Role of prostacyclin and
Klkb1
-/-platelets spread on collagen similar to WT as determined from pixel areas analyzed by ImageJ (Supplemental Figure 9 ). These combined data showed that
-/-platelets functioned normally.
Since there was only a 1.72-fold increase in plasma prostacyclin in Klkb1 -/-mice versus the 3-fold increase previously seen in Bdkrb2 -/-mice 18 , the influence of prostacyclin alone on vascular function was examined. Recently COX-2 derived prostacyclin has been recognized to suppress tissue factor (TF) expression through the NAD + -dependent class III histone deacetylase sirtuin-1 (Sirt1) [29] [30] [31] . The mRNA for both Sirt1 and KLF4
were elevated in Klkb1 -/-aorta ( Figure 5C ). We also found elevated aortic mRNA for Sirt1 and KLF4 in Bdkrb2 -/-mice 17,18 (Supplemental Figure 10) . Additionally, we determined that in aortic lysates, Sirt1 and KLF4 antigen on immunoblot were both increased about 1.7-fold in Klkb1 -/-tissue ( Figure 5D ). On immunofluorescence staining of the carotid artery, vessel wall Sirt1 antigen was 2.5-fold higher in Klkb1 -/-mice ( Figure   5E ). Alternatively, the 1.9-fold increased KLF4 antigen in Klkb1 -/-carotid artery was confined to endothelium ( Figure 5F ). Finally, when Klkb1 -/-mice were treated with nimesulide, there was a significant decrease in Sirt1 and KLF4 mRNA in aorta ( Figure   5C ).
For
We next determined if in vitro treatment of mouse cardiac endothelial cells (MCEC) with carbaprostacyclin (cPGI 2 ), a stable analog of PGl 2 , recapitulated our observations with
-/-and Bdkrb2 -/-aorta. cPGI 2 -treated MCEC had increased Sirt1 and KLF4 mRNA compared to untreated control (p<0.05) ( Figure 5G ). In addition, cPGI 2 For
We next examined TF-induced thrombin generation (TGT) with Klkb1 -/-plasma. When using standard concentration of TF (~3 pM), Klkb1 -/-plasma had slightly decreased TGT (Supplement Figure 11A) . The mean peak height in Klkb1 -/-plasma was 85±6% (n=6) compared to WT (n=6) (p<0.05). The mean total area under the curve (AUC) for TFinduced TGT in Klkb1 -/-plasma was 89±3% (n=6) as in WT (n=6) (p<0.005) (Supplemental Figures 11B & 11C) . When 6-fold less low dose of TF (~0.5 pM) was employed, Klkb1 -/-plasma had markedly reduced thrombin generation when compared to normal plasma ( Figure 6E ). The peak height and area under the curve were both significantly lower in Klkb1 -/-plasma compared to WT ( Figure 6F ). We next examined endogenous TF-induced thrombin generation, i.e. the TGT was performed without adding exogenous TF. In this experiment, mouse plasma was collected into 0.032 g/ml sodium citrate in the absence or presence of rHA-Infestin-4, a XIIa inhibitor to block contact activation that might occur during assay incubation 
-/-mice were protected from thrombosis by elevated plasma prostacyclin and suppressed TF expression in the vessel wall.
Discussion
This investigation on Klkb1 -/-mice indicates that the Mas-prostacyclin axis is an important modulator of arterial thrombosis risk 18, [26] [27] [28] . When there is reduced BK delivery to tissues, the Mas receptor becomes over-expressed and there is elevated plasma prostacyclin ( Figures 5 & 7) . In Bdkrb2 -/-mice, the 3-fold elevation of prostacyclin prolongs the bleeding time and induces a platelet spreading defect on integrins and a GPVI activation defect to reduce murine thrombosis 18 . These mice may have high levels of C1 inhibitor and α 2 -macroglobulin that retard contact activation to prolong the aPTT 35 . Last, the ellagic acid in the aPTT reagent is a contact activator that is weaker than other negatively charged surface additives 36 . Our studies with the Klkb1 -/-mice suggest that other mechanisms for reduced thrombosis, in addition to delayed contact activation, need to be considered.
Plasma kallikrein is recognized as a major enzyme producing BK by cleaving plasma HK and low molecular weight kininogen 6, 37 . We confirmed that Klkb1 -/-plasma has markedly reduced BK ( Figure 4B ) similar to what has been observed in Kgn1 -/-mice 25 .
F12
-/-mice also have reduced BK levels but they are only half normal 20 . The constitutive receptor for BK, B2R (Bdkrb2), is also significantly decreased in Klkb1 -/-kidney ( Figure   4C ). Both Bdkrb2 -/-and Klkb1 -/-mice have defective BK delivery to tissues due to either reduced BK formation and/or reduced B2R 17, 18 . Like Bdkrb2 -/-mice, Klkb1 -/-mice have elevated Mas mRNA and antigen ( Figures 4D-F) . We did not observe increased plasma Figures 5C-5F ). Since the histone deacetylase inhibitor splitomicin corrects delayed thrombosis in Klkb1 -/-mice, Sirt1 is a contributor to thrombosis risk ( Figure   5J ) 30 . Currently, it is not known if the expression of increased KLF4 is interrelated to increased Sirt1 or independently is the result of elevated PGI 2 itself.
Sirt1 and KLF4 are recognized vasculoprotective transcription factors 31, 42 . Sirt1, a deacetylase, may indirectly regulate TF expression by inactivating a coactivator for NF-
. KLF4 may influence TF expression through its ability to influence eNOS and probably are additional mechanisms contributing to the reduced thrombosis 42, 44 .
In conclusion, we have characterized the mechanism for reduced thrombosis in Klkb1 For The areas under the curve were calculated and quantified from the TGT curves in Panels F. Data were normalized to the WT value for each set of experiment.
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